Role of the Biofield Energy Treated Test Formulation on Different Vital Organ Specific Biomarkers

Dublin Core

Title

Role of the Biofield Energy Treated Test Formulation on Different Vital Organ Specific Biomarkers

Subject

Organ Health

Description

The present study was undertaken to evaluate the impact of the Biofield Energy Treated test formulation using cell lines relat-ed with vital organs functioning. In vitro cells based assay were performed to study the effects on the bones, heart, liver, lungs, and brain cells. The test formulation and the cell media was divided into two parts; one part was untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, William Dean Plikerd, USA and labeled as the Biofield Energy Treated (BT) test formulation/media. The test formulation was tested against various activities using cell line assay in their specific medium (Med). The test formulation was tested for cell viability, and the results showed that the test formulation at tested concentrations was found safe and non-toxic. Cytoprotective action of the test formulation showed a significant maximum restoration of cell viability by 133.4% (at 1 µg/mL), 65.7% (at 10 µg/mL), and 86.8% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group in human cardiac fibroblasts cells (HCF) cells, while improved restoration of cell viability by 97.4% (at 1 µg/mL), 85.7% (at 10 µg/mL), and 81.9% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respect-tively, as compared to the untreated test group in HepG2 cells. Cellular restoration in A549 cells was improved by 174.2%, 472.6%, 118%, and 279.2% at 0.1, 1, 10, and 25.5 µg/mL respectively, in the BT-Med + UT-TI group, while 1514%, 1654.8%, 449.8%, and 540.4% improved cellular restoration was reported at 0.1, 1, 10, and 25.5 µg/mL respectively, at BT-Med + BT-TI groups as compared to the untreated test group. ALP activity in MG-63 cells was significantly increased by 93.4% at 50 µg/mL in the UT-Med + BT-TI group, while in Ishikawa cells showed maximum increased ALP activity by 107.4% at 50 µg/mL in the BT-Med + UT-TI group as compared to the untreated group. The maximum percent cellular protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 35.9% at 10 µg/mL in the UT-Med + BT-TI group, while BT-Med + UT-TI group showed increased protection by 69.3% at 1 µg/mL, and improved cellular protection by 119.1% and 44% at 1 and 10 µg/mL respectively, in the BT-Med + BT-TI group as compared to the untreated test group. Alanine amino transferase (ALT) activity was reported in terms of percent cellular protection of HepG2 (liver) cells. Results showed improved HepG2 cells protection (represents decreased ALT activity) by 23.8% (at 10 µg/mL), 98.1% (at 25.5 µg/mL), and 97.6% (at 25 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group. Percentage cellular protection of A549 (lungs) cells (represents increased of SOD activity) was increased by 73.5%, 109.8%, and 97.7% at 0.1 µg/mL in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respect-tively as compared to untreated group. Serotonin level was significantly increased 68% (at 25 µg/mL), 75.7% (at 0.1 µg/mL), and 57.2% (at 25 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to untreated test group in human neuroblastoma cells (SH-SY5Y). However, the relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 16.4% (at 10 µg/mL), 182% (at 50 µg/mL), and 137.1% (at 50 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the untreated in MG-63 cells. In conclusion, Biofield Energy treated test formulation (The Trivedi Effect®) would be significantly useful for multiple organs health that can be used against coronary artery disease, arrhythmias, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, asthma, chronic bronchitis, cystic fibrosis, osteoporosis, etc.

Creator

William Dean Plikerd, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Mayank Gangwar, Snehasis Jana

Publisher

Ommega Publishers

Date

July 2, 2019

Contributor

[no text]

Rights

[no text]

Relation

[no text]

Format

[no text]

Language

English

Type

Journal Article

Identifier

10.15436/2475-6245.19.2519

Coverage

[no text]

Files

TH-131-Mahendra-Trivedi-Role-of-the-Biofield-Energy-Treated-Test-Formulation-on-Different-Vital-Organ-Specific-Biomarkers.pdf

Citation

William Dean Plikerd, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Mayank Gangwar, Snehasis Jana , “Role of the Biofield Energy Treated Test Formulation on Different Vital Organ Specific Biomarkers
,” Mahendra Trivedi, accessed November 17, 2019, https://mahendratrivedi.omeka.net/items/show/432.